IMS Seeking Payer, Government Sector Growth With Comparative Effectiveness Research
This article was originally published in The Pink Sheet Daily
Executive Summary
To direct the effort, the company names John Walsh senior VP payer and government solutions, a new position.
You may also be interested in...
AHRQ To Put More Than Half Of Stimulus CER Funding To Evidence Generation
The Agency for Healthcare Research and Quality is planning to spend $173 million, of the $300 million allocated to it for comparative effectiveness research by the American Recovery and Reinvestment Act, on evidence generation
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.